Correct Answer: D. Parathyroid adenoma
MEN 2B syndrome is characterized by a triad of medullary thyroid carcinoma (MTC), pheochromocytoma, and mucosal neuromas—NOT parathyroid involvement. This is the critical discriminator from MEN 2A, which includes primary hyperparathyroidism as a cardinal feature. In MEN 2B, the RET proto-oncogene mutation (typically M918T) drives neuroendocrine proliferation affecting neural crest–derived tissues (thyroid C-cells, adrenal medulla, mucosal nerve endings) and skeletal development (marfanoid habitus), but the parathyroid glands remain unaffected. Parathyroid adenomas occur in ~80% of MEN 2A patients but are absent in MEN 2B. The absence of hyperparathyroidism in MEN 2B is so consistent that its presence should prompt reconsideration of the diagnosis toward MEN 2A or familial medullary thyroid carcinoma (FMTC). Indian endocrinology guidelines and screening protocols (RNTCP-aligned MTC surveillance) emphasize this distinction because it affects genetic counseling, biochemical screening panels (calcium/PTH not routinely needed in MEN 2B), and family management strategies.
Why the other options are wrong
A. Marfanoid habitus — Marfanoid habitus is a hallmark skeletal feature of MEN 2B, occurring in 80% of patients. The characteristic tall stature, long limbs, and arachnodactyly result from RET-mediated effects on skeletal development. This is a classic clinical sign used for early recognition of MEN 2B in Indian pediatric and endocrinology practice, making it definitively present in the syndrome. **B. Mucosal neuroma** — Mucosal neuromas are pathognomonic for MEN 2B, found on lips, tongue, and throughout the GI tract in nearly all patients. These benign nerve tumors are often the earliest clinical manifestation and serve as a diagnostic clue in childhood. Their presence is so characteristic that absence of mucosal neuromas makes MEN 2B diagnosis unlikely, making this a core feature. **C. Megacolon** — Megacolon (or constipation progressing to Hirschsprung-like disease) occurs in 50% of MEN 2B patients due to extensive mucosal and submucosal neuromas disrupting colonic innervation. This GI manifestation is well-documented in Indian pediatric endocrinology literature and represents a significant morbidity in MEN 2B, distinguishing it from MEN 2A where GI involvement is rare.
High-Yield Facts
- MEN 2B lacks parathyroid adenomas — hyperparathyroidism is a hallmark of MEN 2A (80%) but absent in MEN 2B, making this the key discriminator between the two syndromes.
- MEN 2B triad: medullary thyroid carcinoma (100%), pheochromocytoma (50%), mucosal neuromas (100%) — all RET-driven, neural crest–derived pathology.
- Marfanoid habitus in MEN 2B occurs in ~80% and includes tall stature, long limbs, and arachnodactyly — skeletal manifestation of RET signaling.
- Mucosal neuromas are pathognomonic for MEN 2B and often present in childhood on lips, tongue, and GI tract — earliest diagnostic clue.
- Megacolon/constipation in MEN 2B results from extensive neuromas disrupting colonic innervation, mimicking Hirschsprung disease in ~50% of patients.
- RET M918T mutation is the typical pathogenic variant in MEN 2B, distinct from MEN 2A mutations (codon 634) — explains the different phenotype.
Mnemonics
MEN 2A vs 2B — 'A for Adenoma, B for Bumps' MEN 2A includes parathyroid Adenoma (hyperparathyroidism); MEN 2B has mucosal Bumps (neuromas) instead. Both have MTC and pheo, but parathyroid involvement = 2A. MEN 2B Features — 'MTC, Pheo, Neuromas, Marfan' Medullary Thyroid Carcinoma, Pheochromocytoma, mucosal Neuromas, Marfanoid habitus — the 4 pillars of MEN 2B. No parathyroid.
NBE Trap
NBE may exploit the fact that students conflate MEN 2A and 2B, assuming both have the "classic" endocrine adenomas. The trap is listing parathyroid adenoma as if it applies to all MEN syndromes — testing whether students know the specific phenotypic difference between 2A (adenomas) and 2B (neuromas + marfanoid features).
Clinical Pearl
In Indian clinical practice, a child presenting with mucosal neuromas and marfanoid habitus should trigger immediate RET genetic testing and MTC screening (calcitonin, ultrasound), while parathyroid biochemistry (serum calcium, PTH) is deferred — this distinction saves time and cost in resource-limited settings and prevents unnecessary parathyroid imaging in MEN 2B families.
_Reference: Harrison Ch. 397 (Multiple Endocrine Neoplasia); Robbins Ch. 24 (Endocrine Pathology)_